Kazakhstan

Kazakhstan

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.26 (1.85 - 2.57) 2019 Modelled IHME
2.36 (1.99 - 2.68) 2018 Modelled IHME
2.42 (2.05 - 2.78) 2017 Modelled IHME
2.43 (2.04 - 2.76) 2016 Modelled IHME
2.44 (2.02 - 2.80) 2015 Modelled IHME
2.48 (2.07 - 2.84) 2014 Modelled IHME
2.57 (2.17 - 2.93) 2013 Modelled IHME
2.68 (2.29 - 3.04) 2012 Modelled IHME
2.79 (2.39 - 3.17) 2011 Modelled IHME
2.88 (2.45 - 3.32) 2010 Modelled IHME
2.95 (2.52 - 3.38) 2009 Modelled IHME
3.02 (2.57 - 3.46) 2008 Modelled IHME
3.08 (2.61 - 3.55) 2007 Modelled IHME
3.14 (2.63 - 3.66) 2006 Modelled IHME
3.21 (2.67 - 3.76) 2005 Modelled IHME
3.28 (2.73 - 3.80) 2004 Modelled IHME
3.36 (2.80 - 3.85) 2003 Modelled IHME
3.44 (2.87 - 3.94) 2002 Modelled IHME
3.51 (2.93 - 4.06) 2001 Modelled IHME
3.58 (2.98 - 4.19) 2000 Modelled IHME
3.66 (3.07 - 4.23) 1999 Modelled IHME
3.75 (3.14 - 4.30) 1998 Modelled IHME
3.83 (3.23 - 4.38) 1997 Modelled IHME
3.89 (3.28 - 4.46) 1996 Modelled IHME
3.91 (3.30 - 4.52) 1995 Modelled IHME
3.91 (3.27 - 4.50) 1994 Modelled IHME
3.9 (3.26 - 4.47) 1993 Modelled IHME
3.87 (3.25 - 4.44) 1992 Modelled IHME
3.83 (3.18 - 4.41) 1991 Modelled IHME
3.77 (3.09 - 4.36) 1990 Modelled IHME
1.57 (1.22 - 2.05) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.22 (0.17 - 0.28) 2019 Modelled IHME
0.23 (0.18 - 0.29) 2018 Modelled IHME
0.24 (0.18 - 0.30) 2017 Modelled IHME
0.26 (0.19 - 0.32) 2016 Modelled IHME
0.27 (0.20 - 0.35) 2015 Modelled IHME
0.27 (0.20 - 0.34) 2014 Modelled IHME
0.26 (0.19 - 0.33) 2013 Modelled IHME
0.25 (0.18 - 0.32) 2012 Modelled IHME
0.25 (0.17 - 0.32) 2011 Modelled IHME
0.25 (0.17 - 0.32) 2010 Modelled IHME
0.25 (0.17 - 0.31) 2009 Modelled IHME
0.25 (0.18 - 0.31) 2008 Modelled IHME
0.25 (0.18 - 0.31) 2007 Modelled IHME
0.25 (0.19 - 0.31) 2006 Modelled IHME
0.25 (0.19 - 0.31) 2005 Modelled IHME
0.27 (0.21 - 0.33) 2004 Modelled IHME
0.32 (0.24 - 0.39) 2003 Modelled IHME
0.39 (0.29 - 0.48) 2002 Modelled IHME
0.48 (0.35 - 0.61) 2001 Modelled IHME
0.59 (0.43 - 0.75) 2000 Modelled IHME
0.94 (0.70 - 1.19) 1999 Modelled IHME
1.61 (1.22 - 2.01) 1998 Modelled IHME
2.37 (1.81 - 2.95) 1997 Modelled IHME
2.99 (2.30 - 3.71) 1996 Modelled IHME
3.24 (2.49 - 4.06) 1995 Modelled IHME
3.24 (2.50 - 4.04) 1994 Modelled IHME
3.22 (2.49 - 3.99) 1993 Modelled IHME
3.18 (2.43 - 3.96) 1992 Modelled IHME
3.09 (2.33 - 3.86) 1991 Modelled IHME
2.94 (2.17 - 3.73) 1990 Modelled IHME
0.21 (0.14 - 0.32) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
23 (17 - 31) 2019 Modelled IHME
23 (16 - 31) 2018 Modelled IHME
23 (16 - 31) 2017 Modelled IHME
23 (17 - 31) 2016 Modelled IHME
23 (17 - 31) 2015 Modelled IHME
23 (17 - 31) 2014 Modelled IHME
23 (17 - 31) 2013 Modelled IHME
23 (17 - 31) 2012 Modelled IHME
23 (17 - 31) 2011 Modelled IHME
24 (17 - 31) 2010 Modelled IHME
24 (17 - 32) 2009 Modelled IHME
24 (18 - 32) 2008 Modelled IHME
25 (19 - 33) 2007 Modelled IHME
26 (19 - 34) 2006 Modelled IHME
26 (19 - 34) 2005 Modelled IHME
26 (19 - 34) 2004 Modelled IHME
26 (19 - 35) 2003 Modelled IHME
27 (19 - 35) 2002 Modelled IHME
27 (20 - 36) 2001 Modelled IHME
27 (20 - 36) 2000 Modelled IHME
27 (20 - 36) 1999 Modelled IHME
27 (20 - 36) 1998 Modelled IHME
27 (20 - 36) 1997 Modelled IHME
27 (20 - 37) 1996 Modelled IHME
27 (20 - 37) 1995 Modelled IHME
27 (20 - 37) 1994 Modelled IHME
27 (20 - 36) 1993 Modelled IHME
27 (20 - 36) 1992 Modelled IHME
26 (19 - 35) 1991 Modelled IHME
25 (19 - 34) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
95 2018 Survey/reported WHO/UNICEF
90 2017 Survey/reported WHO/UNICEF
95 2016 Survey/reported WHO/UNICEF
95 2015 Survey/reported WHO/UNICEF
95 2014 Survey/reported WHO/UNICEF
95 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
97 2009 Survey/reported WHO/UNICEF
95 2008 Survey/reported WHO/UNICEF
96 2007 Survey/reported WHO/UNICEF
97 2006 Survey/reported WHO/UNICEF
98 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
99 2003 Survey/reported WHO/UNICEF
99 2002 Survey/reported WHO/UNICEF
95 2001 Survey/reported WHO/UNICEF
98 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
98 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
82 2016 Survey/reported WHO/UNICEF
98 2015 Survey/reported WHO/UNICEF
95 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
95 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
99 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
94 2007 Survey/reported WHO/UNICEF
99 2006 Survey/reported WHO/UNICEF
94 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
99 2003 Survey/reported WHO/UNICEF
95 2002 Survey/reported WHO/UNICEF
95 2001 Survey/reported WHO/UNICEF
99 2000 Survey/reported WHO/UNICEF
90 1999 Survey/reported WHO/UNICEF
49 1998 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
145 (98 - 216) 2016 Survey/reported Larney S et al, 2017
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
2.52 (2.04 - 3.09) 2019 Modelled IHME
2.52 (2.05 - 3.09) 2018 Modelled IHME
2.53 (2.06 - 3.11) 2017 Modelled IHME
2.57 (2.09 - 3.13) 2016 Modelled IHME
2.6 (2.12 - 3.19) 2015 Modelled IHME
2.59 (2.11 - 3.17) 2014 Modelled IHME
2.56 (2.10 - 3.12) 2013 Modelled IHME
2.53 (2.07 - 3.10) 2012 Modelled IHME
2.5 (2.05 - 3.05) 2011 Modelled IHME
2.49 (2.03 - 3.02) 2010 Modelled IHME
2.48 (2.03 - 3.02) 2009 Modelled IHME
2.48 (2.03 - 3.02) 2008 Modelled IHME
2.48 (2.03 - 3.02) 2007 Modelled IHME
2.47 (2.04 - 3.01) 2006 Modelled IHME
2.47 (2.03 - 3.02) 2005 Modelled IHME
2.46 (2.04 - 3) 2004 Modelled IHME
2.45 (2.02 - 2.98) 2003 Modelled IHME
2.44 (2.01 - 2.97) 2002 Modelled IHME
2.42 (1.99 - 2.96) 2001 Modelled IHME
2.42 (1.98 - 2.98) 2000 Modelled IHME
2.41 (1.97 - 2.95) 1999 Modelled IHME
2.41 (1.96 - 2.95) 1998 Modelled IHME
2.41 (1.96 - 2.96) 1997 Modelled IHME
2.4 (1.95 - 2.95) 1996 Modelled IHME
2.4 (1.93 - 2.96) 1995 Modelled IHME
2.39 (1.93 - 2.92) 1994 Modelled IHME
2.38 (1.92 - 2.92) 1993 Modelled IHME
2.36 (1.90 - 2.88) 1992 Modelled IHME
2.34 (1.88 - 2.87) 1991 Modelled IHME
2.32 (1.87 - 2.84) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
3.3 (1 - 6.70) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
58.5 (54 - 63.60) 2005 Modelled Nelson P et al, 2011

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
33 (24 - 43) 2019 Modelled IHME
34 (25 - 43) 2018 Modelled IHME
34 (25 - 44) 2017 Modelled IHME
34 (25 - 43) 2016 Modelled IHME
34 (25 - 43) 2015 Modelled IHME
34 (25 - 43) 2014 Modelled IHME
34 (25 - 43) 2013 Modelled IHME
34 (25 - 43) 2012 Modelled IHME
34 (25 - 43) 2011 Modelled IHME
34 (25 - 43) 2010 Modelled IHME
34 (25 - 43) 2009 Modelled IHME
33 (25 - 42) 2008 Modelled IHME
33 (24 - 42) 2007 Modelled IHME
33 (24 - 41) 2006 Modelled IHME
32 (23 - 41) 2005 Modelled IHME
32 (23 - 41) 2004 Modelled IHME
31 (22 - 40) 2003 Modelled IHME
31 (22 - 40) 2002 Modelled IHME
30 (22 - 39) 2001 Modelled IHME
30 (21 - 39) 2000 Modelled IHME
30 (21 - 39) 1999 Modelled IHME
30 (21 - 39) 1998 Modelled IHME
30 (21 - 39) 1997 Modelled IHME
30 (21 - 39) 1996 Modelled IHME
30 (21 - 39) 1995 Modelled IHME
30 (21 - 39) 1994 Modelled IHME
30 (22 - 39) 1993 Modelled IHME
31 (22 - 40) 1992 Modelled IHME
31 (23 - 40) 1991 Modelled IHME
33 (24 - 41) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (98 - 216) 2016 Survey/reported Larney S et al, 2017
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.26 (%)
2019
(1.85 - 2.57(%))
IHME
HCV (RNA/cAg+)
2.52 (%)
2019
(2.04 - 3.09(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
1,337
2019
(969 - 1,809)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
1,750
2019
(1,302 - 2,323)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.22 (%)
2019, latest modelled
(0.17 - 0.28(%))
IHME

Prevalence PWID

HCV
58.50 (%)
2005, latest modelled
(54 - 63.60(%))
Nelson P et al, 2011

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
95 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
145
2016
(98 - 216)
Larney S et al, 2017
Eligible for HBV generic medicines
Eligible for HCV generic medicines